[go: up one dir, main page]

SMT201900024T1 - Terapia combinata per il trattamento di cancro - Google Patents

Terapia combinata per il trattamento di cancro

Info

Publication number
SMT201900024T1
SMT201900024T1 SM20190024T SMT201900024T SMT201900024T1 SM T201900024 T1 SMT201900024 T1 SM T201900024T1 SM 20190024 T SM20190024 T SM 20190024T SM T201900024 T SMT201900024 T SM T201900024T SM T201900024 T1 SMT201900024 T1 SM T201900024T1
Authority
SM
San Marino
Prior art keywords
cancer
treatment
combination therapy
therapy
combination
Prior art date
Application number
SM20190024T
Other languages
English (en)
Inventor
Steven Hoffman
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/371,076 external-priority patent/US8481498B1/en
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of SMT201900024T1 publication Critical patent/SMT201900024T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37Coumarins, e.g. psoralen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SM20190024T 2012-01-17 2013-01-16 Terapia combinata per il trattamento di cancro SMT201900024T1 (it)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261587420P 2012-01-17 2012-01-17
US13/371,076 US8481498B1 (en) 2012-01-17 2012-02-10 Pharmaceutical compositions and methods
US201261702994P 2012-09-19 2012-09-19
EP13738179.4A EP2804599B1 (en) 2012-01-17 2013-01-16 Combination therapy for the treatment of cancer
PCT/US2013/021714 WO2013109610A1 (en) 2012-01-17 2013-01-16 Pharmaceutical compositions and methods

Publications (1)

Publication Number Publication Date
SMT201900024T1 true SMT201900024T1 (it) 2019-05-10

Family

ID=48799616

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20190024T SMT201900024T1 (it) 2012-01-17 2013-01-16 Terapia combinata per il trattamento di cancro

Country Status (25)

Country Link
EP (2) EP2804599B1 (it)
JP (4) JP6276707B2 (it)
KR (1) KR102172658B1 (it)
CN (2) CN107714684A (it)
AU (4) AU2013209862A1 (it)
BR (1) BR112014017613A2 (it)
CA (1) CA2862689C (it)
CY (1) CY1121450T1 (it)
DK (1) DK2804599T3 (it)
ES (1) ES2706070T3 (it)
HR (1) HRP20190046T1 (it)
HU (1) HUE045314T2 (it)
IL (2) IL233681B (it)
IN (1) IN2014DN06711A (it)
LT (1) LT2804599T (it)
MX (1) MX363579B (it)
NZ (2) NZ628757A (it)
PH (1) PH12014501639B1 (it)
PL (1) PL2804599T3 (it)
PT (1) PT2804599T (it)
RS (1) RS58538B1 (it)
SI (1) SI2804599T1 (it)
SM (1) SMT201900024T1 (it)
WO (1) WO2013109610A1 (it)
ZA (1) ZA201405611B (it)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
JP6276707B2 (ja) * 2012-01-17 2018-02-07 タイム,インコーポレーテッド 薬学的組成物及び方法
US10646552B2 (en) 2012-01-17 2020-05-12 Tyme, Inc. Pharmaceutical compositions and methods
US9724657B2 (en) * 2013-10-22 2017-08-08 Tyme, Inc. High-speed centrifugal mixing devices and methods of use
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
ES2953955T3 (es) * 2014-12-23 2023-11-17 Steven Hoffman Formulaciones transdérmicas
US9687528B2 (en) 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations
CN109195601A (zh) * 2016-03-15 2019-01-11 迪美公司 用于治疗癌症的药物组合物
CA3024501A1 (en) * 2016-05-18 2017-11-23 Tyme, Inc. Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer
CN110167580A (zh) * 2016-11-15 2019-08-23 迪美公司 用于治疗癌症的药物组合物和方法
MX2019006326A (es) * 2016-11-30 2019-07-12 Tyme Inc Derivados de tirosina y composiciones que los comprenden.
EA201992515A1 (ru) * 2017-04-21 2020-04-09 Стивен Хоффман Композиции и способы для лечения ретинопатии
US11534420B2 (en) 2019-05-14 2022-12-27 Tyme, Inc. Compositions and methods for treating cancer
US20210106549A1 (en) * 2019-10-15 2021-04-15 Tyme, Inc. Pharmaceutical compositions and methods
EP4090329A2 (en) * 2020-01-17 2022-11-23 Tyme, Inc. Tyrosine derivatives for modulating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
CN116783212A (zh) * 2020-12-02 2023-09-19 霍夫曼技术有限责任公司 用于调节非人哺乳动物中的癌症的组合物和方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073541A (en) * 1987-11-18 1991-12-17 Administrators Of The Tulane Educational Fund Treatment of small cell lung cancer with somatostatin analogs
DE3823735A1 (de) * 1988-07-13 1989-03-02 Ernst Hajek Verwendung von d-leucin (rechtsdrehende (alpha)-amino-isocapronsaeure) als wirkstoff zur bekaempfung maligner tumoren des schleimhautepithels des gesamten intestinaltraktes einschliesslich pankreas und gallenblase
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
IT1291633B1 (it) * 1997-04-22 1999-01-11 Pharmaconsult S A S Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride
EP1950224A3 (en) * 1998-03-09 2008-12-17 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
AU775289B2 (en) * 1998-08-21 2004-07-29 Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
JP2002128304A (ja) 2000-10-20 2002-05-09 Nec Eng Ltd 給紙装置
KR20050089857A (ko) * 2002-12-26 2005-09-08 아지노모토 가부시키가이샤 간암 발생 및 진행 억제제
ATE431140T1 (de) * 2005-03-11 2009-05-15 Gpc Biotech Ag Antiproliferative kombinations-therapie mit satraplatin oder jm118 und docetaxel
WO2008027837A2 (en) * 2006-08-28 2008-03-06 The Regents Of The University Of California Small molecule potentiator of hormonal therapy for breast cancer
JP5073541B2 (ja) 2007-05-09 2012-11-14 ルネサスエレクトロニクス株式会社 半導体記憶装置
KR20100063717A (ko) * 2007-09-11 2010-06-11 몬도바이오테크 래보래토리즈 아게 치료제로서의 cart 펩티드 배합물의 용도
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
EP2558102A4 (en) * 2010-04-16 2013-09-25 Davos Life Science Pte Ltd SYNERGISTIC INTERACTION OF AT LEAST ONE COMPONENT OF VITAMIN E AND TYROSINASE INHIBITORS FOR DERMATOLOGICAL APPLICATIONS
JP6276707B2 (ja) 2012-01-17 2018-02-07 タイム,インコーポレーテッド 薬学的組成物及び方法

Also Published As

Publication number Publication date
JP6789916B2 (ja) 2020-11-25
AU2020201683A1 (en) 2020-03-26
IL233681A0 (en) 2014-09-30
IL252566A0 (en) 2017-07-31
KR20140135704A (ko) 2014-11-26
EP2804599A4 (en) 2015-10-21
JP7095028B2 (ja) 2022-07-04
AU2013209862A1 (en) 2014-09-04
CN104220057B (zh) 2017-11-03
SI2804599T1 (sl) 2019-05-31
IL233681B (en) 2019-07-31
JP2018065848A (ja) 2018-04-26
DK2804599T3 (en) 2019-02-04
JP2020172521A (ja) 2020-10-22
AU2022202113A1 (en) 2022-04-14
BR112014017613A2 (pt) 2017-07-04
PH12014501639A1 (en) 2014-10-13
IN2014DN06711A (it) 2015-05-22
EP2804599B1 (en) 2018-10-17
HUE045314T2 (hu) 2019-12-30
CN107714684A (zh) 2018-02-23
WO2013109610A1 (en) 2013-07-25
HRP20190046T1 (hr) 2019-05-03
CA2862689C (en) 2020-03-10
JP2015509101A (ja) 2015-03-26
ZA201405611B (en) 2015-06-24
CY1121450T1 (el) 2020-05-29
AU2018203026A1 (en) 2018-05-17
PH12014501639B1 (en) 2023-02-22
JP2022095894A (ja) 2022-06-28
KR102172658B1 (ko) 2020-11-02
NZ721280A (en) 2017-08-25
LT2804599T (lt) 2019-04-10
RS58538B1 (sr) 2019-04-30
EP3488848A1 (en) 2019-05-29
IL252566B (en) 2020-07-30
MX363579B (es) 2019-03-27
JP6276707B2 (ja) 2018-02-07
ES2706070T3 (es) 2019-03-27
NZ628757A (en) 2016-07-29
MX2014008640A (es) 2015-03-09
CA2862689A1 (en) 2013-07-25
PL2804599T3 (pl) 2019-06-28
EP2804599A1 (en) 2014-11-26
PT2804599T (pt) 2019-01-28
CN104220057A (zh) 2014-12-17

Similar Documents

Publication Publication Date Title
IL289300A (en) Combined treatment for cancer
PT3033086T (pt) Terapia de combinação para o tratamento de cancro
RS58538B1 (sr) Kombinovana terapija za lečenje kancera
IL263661A (en) Combination therapy for the treatment of glioblastoma
IL263781A (en) Combined treatment of ovarian cancer
EP2788378A4 (en) ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER
EP2903644A4 (en) TREATMENT OF CANCER
ZA201300762B (en) Novel combination therapy for the treatment of cancer
GB201217892D0 (en) Treatment of cancer
IL236321A0 (en) Combined treatment for cancer and immunosuppression
IL275636A (en) Medical combination for cancer treatment
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
PL2872176T3 (pl) Karboranyloporfiryny do stosowania w leczeniu raka
GB2519004B (en) Quinone compounds and their uses for the treatment of cancer
HK40089826A (en) Combination therapy for treating cancer
GB201217890D0 (en) Treatment of cancer
IL233495A0 (en) Combination for cancer treatment
IL239231A0 (en) Combined cancer treatment
GB201222950D0 (en) Combination treatment of cancer
GB201222949D0 (en) Combination Treatment of Cancer
GB201208296D0 (en) Treatment of cancer